Physician profile
Rina Edelson
NPI 1326615840
$881.57
in general payments reported to CMS, 2019-2025
14 companies · $451 in 2025
The $451 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.28 · 2023: $36.94 · 2024: $378 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $865.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $257.19 | 2024-2025 | Cequr Simplicity |
| Amgen INC. | $124.74 | 2024 | Evenity |
| Corcept Therapeutics | $113.55 | 2025 | Korlym |
| Collegium Pharmaceutical, INC. | $78.94 | 2025 | Jornay Pm |
| Alk-Abello, INC | $73.40 | 2024-2025 | Neffy, Grastek, Ragwitek |
| Cranial Technologies, INC | $52.15 | 2024-2025 | Doc Band |
| Sanofi-Aventis U.S. LLC | $41.65 | 2024-2025 | |
| Ironshore Pharmaceuticals INC. | $25.21 | 2024 | |
| Biogen, INC. | $22.26 | 2025 | Spinraza |
| Ultragenyx Pharmaceutical INC. | $21.44 | 2025 | Dojolvi |
| Kaleo, INC. | $21.25 | 2023 | Auvi-Q |
| Tris Pharma INC | $17.82 | 2024 | Dyanavel Xr |
| Alvogen INC | $16.28 | 2022 | |
| Lilly USA, LLC | $15.69 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rina Edelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.